Each film-coated tablet contains Flupentixol Hydrochloride BP equivalent to Flupentixol 0.5 mg and Melitracen Hydrochloride INN equivalent to Melitracen 10 mg.
Pharmacological Effects
Angenta® consists of two well-known and well-proven compounds: flupentixol, a neuroleptic with anxiolytic and antidepressant properties when given in small doses, and melitracen, a bipolar thymoleptic with activating properties in low doses. In combination, these compounds create a preparation with antidepressant, anxiolytic, and activating properties.
The maximal serum concentration is reached approximately 4 hours after oral administration of both flupentixol and melitracen. The biological half-life of flupentixol is about 35 hours, while that of melitracen is approximately 19 hours. The combination of flupentixol and melitracen does not appear to influence the pharmacokinetic properties of the individual compounds.
Angenta® is indicated for the treatment of:
Anxiety, depression, and apathy.
Psychogenic depression.
Depressive neuroses.
Masked depression.
Psychosomatic conditions accompanied by anxiety and apathy.
Menopausal depressions.
Dysphoria and depression in alcoholics and drug addicts.
Adults: Usually 2 tablets daily, one in the morning and one at noon. In severe cases, the morning dose may be increased to 2 tablets.
Elderly Patients: 1 tablet in the morning.
Maintenance Dose: Typically, 1 tablet in the morning.
In cases of insomnia or severe restlessness, additional treatment with a sedative during the acute phase is recommended.
Angenta® is contraindicated in the following situations:
Immediate recovery phase after myocardial infarction.
Defects in bundle-branch conduction.
Untreated narrow-angle glaucoma.
Acute alcohol, barbiturate, or opiate intoxication.
Patients who have taken an MAO inhibitor within the past two weeks.
Not recommended for excitable or overactive patients, as its activating effect may exacerbate these characteristics.
At recommended doses, side effects are rare. Possible side effects include transient restlessness and insomnia.
If the patient was previously treated with sedative tranquilizers, these should be withdrawn gradually.
Angenta® is preferably not recommended during pregnancy and lactation.
Angenta® may enhance the effects of alcohol, barbiturates, and other CNS depressants.
Concurrent use with MAO inhibitors may cause hypertensive crises.
Neuroleptics and thymoleptics reduce the antihypertensive effects of guanethidine and similar compounds, while thymoleptics enhance the effects of adrenaline and noradrenaline.
Symptoms: In cases of overdose, symptoms of melitracen intoxication, particularly those of an anticholinergic nature, predominate. Extrapyramidal symptoms due to flupentixol may occur less frequently.
Treatment: Symptomatic and supportive measures should be taken. Gastric lavage should be performed as soon as possible, and activated charcoal may be administered. Measures to support the respiratory and cardiovascular systems should be implemented. Epinephrine (adrenaline) must not be used in such patients. Convulsions may be treated with diazepam, and extrapyramidal symptoms may be managed with biperiden.
Store in a cool, dry place. Keep out of reach of children.
